Ovarian Cancer: The Role of Functional Imaging as an End Point in Clinical Trials

2010 ◽  
Vol 20 (6) ◽  
pp. 971-978 ◽  
Author(s):  
Evis Sala ◽  
Nandita DeSouza ◽  
Susanna I. Lee ◽  
Mostafa Atri ◽  
Hedvig Hricak
Keyword(s):  
Ovarian Cancer ◽  
Clinical Trials ◽  
Functional Imaging ◽  
Gynecologic Cancer ◽  
Position Paper ◽  
Gynaecological Cancer ◽  
End Point ◽  
Early Treatment Response ◽  
Anatomical Imaging

The Gynaecological Cancer InterGroup conducts collaborative trials in gynecologic cancer and also aims to develop standards that can be used to strengthen all aspects of study methodology. There is an urgent need to develop more refined imaging end points that can be used as early treatment response biomarkers in ovarian cancer. Therefore, the Gynaecological Cancer InterGroup commissioned an expert position paper on the role of functional imaging as an end point in clinical trials in ovarian cancer. In this position paper, we state the limitation of current anatomical imaging methods used in clinical trials, highlight the potential of functional imaging, and provide key recommendations on the use of functional imaging as an end point in ovarian cancer clinical trials.

Clinical Trials in Recurrent Ovarian Cancer

2011 ◽  
Vol 21 (4) ◽  
pp. 771-775 ◽  
Author(s):  
Michael Friedlander ◽  
Edward Trimble ◽  
Anna Tinker ◽  
David Alberts ◽  
Elisabeth Avall-Lundqvist ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Clinical Trials ◽  
Gynecologic Cancer ◽  
Recurrent Ovarian Cancer ◽  
Consensus Conference ◽  
Ca 125 ◽  
Therapeutic Approaches ◽  
Cooperative Research ◽  
International Consensus

The 4th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup was held in Vancouver, Canada, in June 2010. Representatives of 23 cooperative research groups studying gynecologic cancers gathered to establish international consensus on issues critical to the conduct of large randomized trials. Group C, 1 of the 3 discussion groups, examined recurrent ovarian cancer, and we report the consensus reached regarding 4 questions. These included the following: (1) What is the role of cytoreductive surgery for recurrent ovarian cancer? (2) How do we define distinct patient populations in need of specific therapeutic approaches? (3) Should end points for trials with recurrent disease vary from those of first-line trials? (4) Is CA-125 progression alone sufficient for entry/eligibility into clinical trials?

scholarly journals The Role of Operative Laparoscopy in Gynecologic Oncology

1996 ◽  
Vol 2 (4) ◽  
pp. 185-188 ◽  
Author(s):  
E. M. Hartenbach ◽  
J. M. Fowler
Keyword(s):  
Ovarian Cancer ◽  
Clinical Trials ◽  
Gynecologic Oncology ◽  
Paraaortic Lymph Node ◽  
Node Dissection ◽  
Operative Laparoscopy ◽  
Pelvic Malignancies ◽  
Potential Applications ◽  
Paraaortic Lymph Node Dissection

The potential applications of operative laparoscopy have expanded with improvements in technology and instrumentation. With newly developed techniques to complete both pelvic and paraaortic lymph node dissection, the use of the laparoscope has increased in patients with pelvic malignancies. Gynecologic oncologists are currently incorporating the techniques of operative laparoscopy in the management of patients with cervical, endometrial, and ovarian cancer. Multicenter prospective clinical trials are necessary to further define the role of laparoscopy in gynecologic oncology.

scholarly journals Harmonising clinical trials within the Gynecologic Cancer InterGroup: consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference

2017 ◽  
Vol 28 ◽  
pp. viii30-viii35 ◽  
Author(s):  
M.A. Bookman ◽  
A. Okamoto ◽  
G. Stuart ◽  
N. Yanaihara ◽  
D. Aoki ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Clinical Trials ◽  
Unmet Needs ◽  
Gynecologic Cancer ◽  
Consensus Conference

scholarly journals Ovarian Cancer Translational Activity of the Multicenter Italian Trial in Ovarian Cancer (MITO) Group: Lessons Learned in 10 Years of Experience

Cells ◽  
2020 ◽  
Vol 9 (4) ◽  
pp. 903
Author(s):  
Daniela Califano ◽  
Daniela Russo ◽  
Giosuè Scognamiglio ◽  
Nunzia Simona Losito ◽  
Anna Spina ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Clinical Trials ◽  
Clinical Data ◽  
Gynecologic Cancer ◽  
Years Of Experience ◽  
Web Based ◽  
Formalin Fixed Paraffin ◽  
Formalin Fixed Paraffin Embedded ◽  
Embedded Blocks ◽  
Formalin Fixed

Ovarian cancer is the most lethal gynecological cancer, and despite years of research, with the exception of a BRCA mutation driving the use of PARP inhibitors, no new prognostic/predictive biomarkers are clinically available. Improvement in biomarker selection and validation may derive from the systematic inclusion of translational analyses into the design of clinical trials. In the era of personalized medicine, the prospective centralized collection of high-quality biological material, expert pathological revision, and association to well-controlled clinical data are important or even essential added values to clinical trials. Here, we present the academic experience of the MITO (Multicenter Italian Trial in Ovarian Cancer) group, including gynecologists, pathologists, oncologists, biostatisticians, and translational researchers, whose effort is dedicated to the care and basic/translational research of gynecologic cancer. In our ten years of experience, we have been able to collect and process, for translational analyses, formalin-fixed, paraffin-embedded blocks from more than one thousand ovarian cancer patients. Standard operating procedures for collection, shipping, and processing were developed and made available to MITO researchers through the coordinating center’s web-based platform. Clinical data were collected through dedicated electronic case report forms hosted in a web-based electronic platform and stored in a central database at the trial’s coordinating center, which performed all the analyses related to the proposed translational researches. During this time, we improved our strategies of block management from retrospective to prospective collection, up to the design of a prospective collection with a quality check for sample eligibility before patients’ accrual. The final aim of our work is to share our experience by suggesting a guideline for the process of centralized collection, revision processing, and storing of formalin-fixed, paraffin-embedded blocks for translational purposes.

Role of Molecular Agents and Targeted Therapy in Clinical Trials for Women With Ovarian Cancer

2011 ◽  
Vol 21 (4) ◽  
pp. 763-770 ◽  
Author(s):  
Jonathan A. Ledermann ◽  
Christian Marth ◽  
Mark S. Carey ◽  
Michael Birrer ◽  
David D.L. Bowtell ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Clinical Trials ◽  
Targeted Therapy ◽  
Predictive Biomarkers ◽  
Therapeutic Agents ◽  
Careful Consideration ◽  
Consensus Conference ◽  
Molecular Pathways ◽  
New Agents

There is now a greater understanding of the molecular pathways in ovarian cancer, and using this knowledge, a large number of new therapeutic agents can be tested. The success of these drugs will depend on selecting drugs that target known key dysfunctional molecular pathways. To make best use of these compounds, prognostic and predictive biomarkers need to be identified. Novel methods of assessment such as functional imaging need to be developed as additional biological end points to evaluate these therapies. Promising antitumor activity has been observed with some drugs, and careful consideration is needed to determine in what circumstances new agents, such as antiangiogenic compounds, could be considered as a standard therapy. These areas were discussed at the 4th Ovarian Cancer Consensus Conference.

scholarly journals Transcriptomic and Immunohistochemical Profiling of SLC6A14 in Pancreatic Ductal Adenocarcinoma

2015 ◽  
Vol 2015 ◽  
pp. 1-10 ◽  
Author(s):  
Alan R. Penheiter ◽  
Sibel Erdogan ◽  
Stephen J. Murphy ◽  
Steven N. Hart ◽  
Joema Felipe Lima ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Functional Imaging ◽  
Basic Amino Acid ◽  
Tissue Microarrays ◽  
Ductal Adenocarcinoma ◽  
Transcriptional Level ◽  
Normal Pancreas ◽  
Anatomical Imaging

We used a target-centric strategy to identify transporter proteins upregulated in pancreatic ductal adenocarcinoma (PDAC) as potential targets for a functional imaging probe to complement existing anatomical imaging approaches. We performed transcriptomic profiling (microarray and RNASeq) on histologically confirmed primary PDAC tumors and normal pancreas tissue from 33 patients, including five patients whose tumors were not visible on computed tomography. Target expression was confirmed with immunohistochemistry on tissue microarrays from 94 PDAC patients. The best imaging target identified was SLC6A14 (a neutral and basic amino acid transporter). SLC6A14 was overexpressed at the transcriptional level in all patients and expressed at the protein level in 95% of PDAC tumors. Very little is known about the role of SLC6A14 in PDAC and our results demonstrate that this target merits further investigation as a candidate transporter for functional imaging of PDAC.

scholarly journals The Role of Dysregulated Glucose Metabolism in Epithelial Ovarian Cancer

2010 ◽  
Vol 2010 ◽  
pp. 1-13 ◽  
Author(s):  
L. D. Kellenberger ◽  
J. E. Bruin ◽  
J. Greenaway ◽  
N. E. Campbell ◽  
R. A. Moorehead ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Gynecologic Cancer ◽  
Epidemiological Studies ◽  
Direct Effects ◽  
Health Issues ◽  
Obesity And Diabetes ◽  
Energy Sensing ◽  
The Warburg Effect

Epithelial ovarian cancer (EOC) is the most lethal gynecologic cancer and also one of the most poorly understood. Other health issues that are affecting women with increasing frequency are obesity and diabetes, which are associated with dysglycemia and increased blood glucose. The Warburg Effect describes the ability of fast-growing cancer cells to preferentially metabolize glucose via anaerobic glycolysis rather than oxidative phosphorylation. Recent epidemiological studies have suggested a role for hyperglycemia in the pathogenesis of a number of cancers. If hyperglycemia contributes to tumour growth and progression, then it is intuitive that antihyperglycemic drugs may also have an important antitumour role. Preliminary reports suggest that these drugs not only reduce available plasma glucose, but also have direct effects on cancer cell viability through modification of molecular energy-sensing pathways. This review investigates the effect that hyperglycemia may have on EOC and the potential of antihyperglycemic drugs as therapeutic adjuncts.

The Global Impact of the Gynecologic Cancer InterGroup in Enhancing Clinical Trials in Ovarian Cancer

2011 ◽  
Vol 21 (4) ◽  
pp. 746-749 ◽  
Author(s):  
Monica Bacon ◽  
Henry Kitchener ◽  
Gavin C.E. Stuart ◽  
Jan B. Vermorken
Keyword(s):  
Ovarian Cancer ◽  
Clinical Trials ◽  
Gynecologic Oncology ◽  
Gynecologic Cancer ◽  
Consensus Conference ◽  
International Forum ◽  
Gynecologic Cancers ◽  
International Differences ◽  
Global Impact ◽  
Multiple Issues

The Gynecologic Cancer InterGroup (GCIG) has developed from a small network of ovarian cancer researchers to a large international forum addressing multiple issues related to research in gynecologic cancers. Member groups of the GCIG have collaboratively conducted pivotal clinical trials in cancers of the ovary, endometrium, and cervix. The participation of operational and statistical personnel from the GCIG member groups has facilitated a collegial approach to international differences and restrictions.One of the powerful initiatives of the GCIG is the facilitation of the Ovarian Cancer Consensus Conference every few years. The 4th Ovarian Cancer Consensus Conference was held in Vancouver, Canada, in June 2010, and the resulting publications (herein) provide an invaluable resource to researchers in the field of gynecologic oncology.

scholarly journals The Role of Proteomics in the Diagnosis and Treatment of Ovarian Cancer

2005 ◽  
Vol 1 (3) ◽  
pp. 365-374 ◽  
Author(s):  
Nana E Tchabo ◽  
Elizabeth A Guancial ◽  
Josephine A Czechowicz ◽  
Elise C Kohn
Keyword(s):  
Ovarian Cancer ◽  
Early Stage ◽  
Gynecologic Cancer ◽  
Western World ◽  
Stage Disease ◽  
Screening Strategies ◽  
Alternative Means ◽  
Tissue Lysate ◽  
New Biomarkers

Ovarian cancer is the leading cause of gynecologic cancer death in the Western world and more than 70% of patients are diagnosed with advanced stage disease. The high mortality rate is due to the difficulty in the early detection of ovarian cancer. Current screening strategies lack the necessary sensitivity and specificity to reliably and accurately diagnose affected women, prompting investigators to seek alternative means of analysis found in protein pathways and networks. Proteomics seeks to advance the understanding of how proteins interact in cancer and may provide a mechanism for early stage diagnosis. The proteomic techniques of laser capture microdissection, mass spectrometry and tissue lysate arrays have led to the discovery of new biomarkers and the identification, development and approval of a number of targeted therapeutic agents. Following validation through clinical trials, the application of these techniques will contribute to the changing paradigm of cancer detection and treatment toward personalized medicine.

Sign in / Sign up

Export Citation Format

Share Document